Evidence map›Paper›PMID 38638055›Full record

Trial reportCancer science2024

Efficacy and biomarker analysis of second-line nab-paclitaxel plus sintilimab in patients with advanced biliary tract cancer.

Xiaofen Li, Nan Zhou, Yu Yang, Zijian Lu, Hongfeng Gou

Registry-linked trialOpen access · goldAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cancer science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06662877 (Anlotinib Plus Nab-Paclitaxels and S-1 Versus FOLFOX for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06662877 phase2 / phase3not yet recruitingnot on this map

Anlotinib Plus Nab-Paclitaxels and S-1 Versus FOLFOX for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment: a Phase 2/3, Multi-centric Double-stage Randomized Controlled Trial

TypeinterventionalSponsorSun Yat-sen UniversityRan2024 to 2029Enrolled206ConditionsBiliary Tract Cancer, Second Line Treatment, Chemotherapy, Tyrosine Kinase InhibitorArmsAlbumin-bound Paclitaxel + Tegafur Gimeracil Oteracil (S-1) + Anlotinib, Oxaliplatin + Leucovorin + Fluorouracil (FOLFOX regimen)
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Xiaofen LiDepartment of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Nan ZhouDepartment of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Yu YangDepartment of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Zijian LuDepartment of Pathology, West China Hospital, Sichuan University, Chengdu, China.
Hongfeng GouDepartment of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.ORCID https://orcid.org/0000-0002-2071-6773
Sichuan University · CN

Funding

Health Commission of Sichuan Province Program 21PJ007
6 · The paper itself

Abstract

Biliary tract cancer (BTC) is a highly aggressive malignancy with limited second-line therapy. We conducted this phase 2 trial to evaluate the efficacy and safety of second-line nab-paclitaxel plus sintilimab in advanced BTC. Histologically confirmed advanced BTC patients with documented disease progression after first-line chemotherapy were enrolled. Subjects received nab-paclitaxel 125 mg/m

Indexed as

AlbuminsAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBiliary Tract NeoplasmsBiomarkers, TumorPaclitaxelAdultAgedB7-H1 AntigenFemaleHumansLymphocytes, Tumor-InfiltratingMaleMiddle AgedProgression-Free SurvivalTreatment Outcome130-nm albumin-bound paclitaxelAlbuminsAntibodies, Monoclonal, HumanizedB7-H1 AntigenBiomarkers, TumorCD274 protein, humanPaclitaxelsintilimabbiliary tract cancerbiomarkernab‐paclitaxelsecond‐line treatmentSintilimab

Identifiers

PMID38638055
PMCPMC11247563
OpenAlexW4394958783

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.